Key terms
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NBIX news
May 03
1:17pm ET
Neurocrine presents data from CAHtalyst Pediatric Phase 3 clinical study
May 03
7:11am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)
May 03
7:10am ET
Neurocrine’s Promising Future: Buy Rating Justified by Untapped Potential and Strong Operational Strategy
May 03
6:53am ET
Maintaining Hold on Neurocrine Biosciences Amidst Pipeline Potential and Market Valuation Concerns
May 03
6:39am ET
Neurocrine price target raised to $150 from $140 at Citi
May 02
8:45am ET
Neurocrine price target raised to $164 from $154 at Canaccord
May 02
8:21am ET
Neurocrine price target raised to $216 from $200 at Oppenheimer
May 02
8:16am ET
Buy Rating on Neurocrine: Strong Foundations and Promising Pipeline
May 02
8:08am ET
Oppenheimer Sticks to Its Buy Rating for Neurocrine (NBIX)
May 02
7:43am ET
Neurocrine price target raised to $169 from $150 at Barclays
May 02
7:36am ET
Neurocrine Biosciences: A Balanced Hold Rating Amidst Revenue Growth and Rising Expenses
May 02
6:52am ET
Neurocrine price target raised to $170 from $164 at Guggenheim
May 02
6:32am ET
Neurocrine’s Innovative Schizophrenia Treatment and Strong Market Strategy Merit a Buy Rating
May 02
6:11am ET
Neurocrine price target raised to $160 from $150 at H.C. Wainwright
May 02
5:21am ET
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Moderna (MRNA) and Neurocrine (NBIX)
May 02
4:55am ET
Neurocrine management to meet with Oppenheimer
May 02
3:50am ET
Neurocrine (NBIX) Receives a Buy from Barclays
May 01
11:55pm ET
Buy Rating Affirmed for Neurocrine Biosciences on Strong Performance and Promising Pipeline
May 01
8:19am ET
Analysts Offer Insights on Healthcare Companies: Stryker (SYK), Charles River Labs (CRL) and Neurocrine (NBIX)
May 01
8:18am ET
Neurocrine’s Hold Rating Affirmed Amid Earnings Shortfall and Steady Sales Outlook
May 01
7:16am ET
Neurocrine backs FY24 INGREZZA net product sales view $2.1B-$2.2B
May 01
7:15am ET
Neurocrine reports Q1 adjusted EPS $1.20, consensus $1.01
Apr 30
5:15pm ET
Neurocrine announces FDA approval of INGREZZA SPRINKLE capsules
Apr 30
4:12pm ET
Neurocrine management to meet with Oppenheimer
Apr 26
3:15am ET
Promising Outlook for Neurocrine’s NBI-‘845 in MDD Market Based on Strong Phase 2 Results and Competitive Positioning
Apr 26
2:17am ET
Buy Rating Affirmed for Neurocrine on Promising Phase 2 SAVITRI Study Results
Apr 26
2:12am ET
Maintaining Hold on Neurocrine Amid Promising Yet Uncertain Clinical Developments
Apr 24
9:36am ET
Tesla, Airbnb upgraded: Wall Street’s top analyst calls
Apr 24
7:56am ET
Jefferies Sticks to Its Buy Rating for Neurocrine (NBIX)
Apr 24
7:50am ET
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Day One Biopharmaceuticals (DAWN) and Roche Holding AG (OtherRHHVF)
Apr 24
7:30am ET
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), HealthStream (HSTM) and Vertex Pharmaceuticals (VRTX)
No recent press releases are available for NBIX
NBIX Financials
Key terms
Ad Feedback
NBIX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NBIX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
